Name: AAN 2020 Data Release: Ofatumumab for Relapsing MS
Uploaded: 2020-05-22T13:00:07Z
Description: AAN 2020 Data Release: Ofatumumab for Relapsing MS

Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Kenneth Ngo, MD, medical director for the Brain Injury Program at Brooks Rehabilitation’s 3 inpatient hospitals, highlighted how cotreatment between music therapy and physical therapy can significantly improve the overall quality of life for patients with Parkinson disease. 

The Role of Music & Movement in Parkinson Disease Treatment

Videos

The chief scientific officer at Athira talked about the potential of hepatocyte growth factor compounds in promoting neurotrophic signaling and providing broad neuroprotection across neurodegenerative diseases. [WATCH TIME: 6 minutes]

Promise of Neuroprotection in Neurodegenerative Diseases Through HGF Compounds: Kevin Church, PhD

The chair of neurology at Massachusetts General Hospital talked about results from the phase 2b PARADIGM trial assessing PrimeC, an ALS combination agent that consists of ciprofloxacin and celecoxib. [WATCH TIME: 4 minutes]

Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC: Merit Cudkowicz, MD, MSc

After 2 years of treatment, EDG-5506, otherwise known as sevasemten, was well-tolerated, with rapid and sustained decreases in biomarkers of muscle damage.

Investigational Agent EDG-5506 Shows Promising 2-Year Data in Becker Muscular Dystrophy

The professor of neurology at the NYU Grossman School of Medicine provided commentary on a study that demonstrated the benefits of using tDCS along with sleep language training to promote naming in primary progressive aphasia. [WATCH TIME: 5 minutes]

Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Leigh Charvet, PhD

, has been with the team since October 2019. Follow him on Twitter 

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center provided commentary on the need to properly diagnose Lennox-Gastaut syndrome and the negative downstream impacts of misdiagnosis or underdiagnosing patients.

NeuroVoices: Scott Perry, MD, on the Intricacies and Value of Diagnosing Lennox-Gastaut Syndrome

Lauren Seidman, a second-year medical student at NYU Langone’s Grossman School of Medicine, provided perspective on a poster at AAN 2024 highlighting the use of binocular visual function testing in Alzheimer disease.

Understanding the Clinical Utility of Low-Contrast Letter Acuity and RAN Tasks in Alzheimer Disease

Director, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic 

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the safety of ravulizumab and the ways to avoid risks of meningococcal infection. [WATCH TIME: 3 minutes]

Safety Considerations for Ravulizumab in NMOSD: Sean Pittock, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

AAN 2020: Multiple Sclerosis Treatment Considerations

Multiple Sclerosis and Risk of COVID-19

Disease-Modifying Therapies for MS During COVID-19

AAN 2020: Real-World Data on Cladribine Tablets for MS

Multiple Sclerosis: Takeaways From AAN 2020

MS Treatment Optimization During COVID-19

Treating Patients With MS During the COVID-19 Pandemic

AAN 2020 Data Release: Ofatumumab for Relapsing MS

Novel Oral Therapy for MS: AAN Data Updates

The Future of Multiple Sclerosis Management

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

The News Network video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases.